NUVAXOVID COVID-19 VACCINE (adjuvanted)

SARS-CoV-2 rS (NVX-CoV2373)

Consumer Medicine Information

This vaccine has **provisional approval** in Australia to prevent COVID-19 disease caused by SARS-CoV-2 virus in people aged 18 years and older. This approval has been granted on the basis of short-term efficacy and safety data. Evidence of longer term efficacy and safety from ongoing clinical trials and vaccination in the community continues to be gathered and assessed.

This leaflet provides important information about using NUVAXOVID. **You should also speak to your healthcare provider if you would like further information or if you have any concerns or questions about receiving NUVAXOVID.**

Where to find information in this leaflet:

1. **Why am I being given NUVAXOVID?**
2. **What should I know before I am given NUVAXOVID?**
3. **What if I am taking other medicines or vaccines?**
4. **How will I be given NUVAXOVID?**
5. **What should I know while being given NUVAXOVID?**
6. **Are there any side effects?**
7. **Product details**

1. Why am I being given NUVAXOVID?

NUVAXOVID contains the active ingredient SARS-CoV-2 rS (NVX-CoV2373).

NUVAXOVID is a protein vaccine that works by triggering your immune system to produce antibodies and blood cells to work against the virus, to protect you against COVID-19 disease.

NUVAXOVID also contains an adjuvant, a substance included in certain vaccines to accelerate, improve and/or prolong the protective effects of the vaccine.

NUVAXOVID is a vaccine used to prevent COVID-19 disease caused by the SARS-CoV-2 virus in people aged 18 years and older.